Intelligence that changes decisions, not just slides
We help brand and strategy teams decide what to watch and why, then run the monitoring — pipelines, trials, regulatory events and payer decisions — and translate signals into implications for your evidence, access and launch plans.
Strategic advisory
Before any deliverable is scoped, our consultants work with your leadership to answer the questions that determine whether the evidence will change a decision.
- Competitive landscape and scenario planning workshops
- Evidence-benchmarking against competitor HTA and publication strategies
- Launch-sequence and market-entry implications analysis
- Partnering and licensing due diligence: assessing in- or out-licensing assets through the HTA, JCA and US payer-value lens before the deal is signed
- Ongoing intelligence governance and stakeholder briefings
Evidence generation capabilities
Pipeline & Trial Tracking
Systematic monitoring of clinical trial registries, pipelines and milestone events.
Conference Intelligence
Targeted coverage of ISPOR, ASCO, ESMO, ADA, BIO and other key congresses and partnering events.
Regulatory, HTA & Payer Landscape
Tracking of FDA, EMA, NICE, G-BA and other agency decisions alongside reimbursement status, price benchmarking and access barriers.
Asset & Partnering Due Diligence
Evidence-package, comparator-landscape and access-readiness assessment of licensing candidates for BD and portfolio teams.
Competitor Evidence Audits
Structured assessment of competitor evidence packages and publication strategies.
Newsletters & Dashboards
Periodic intelligence digests and interactive dashboards for stakeholders.
AI-assisted strategic analysis
Not every project needs it. For the engagements below, our consultants draw on in-house AI tools to analyse faster and more consistently — and you receive the insight as a strategic report with recommendations.
Scenario modelling & horizon scanning
For launch and lifecycle decisions, we model forward-looking landscape scenarios — competitor events, regulatory and payer shifts — and translate them into recommended moves.
Partnering & asset-landscape intelligence
For BD and portfolio decisions, we use in-house AI tools to index and score partnering assets by therapeutic area, stage, modality and geography — enriched with congress-floor intelligence and an EU JCA / US payer-value readiness lens — so shortlists arrive pre-qualified, with our consultants' judgment attached.
Questions clients ask about Competitive Intelligence
Competitive intelligence changes more decisions when it is combined with our HEOR & Global Market Access Strategy, Real World Evidence Strategy and Scientific Communications capabilities.
What does pharma competitive intelligence cover?+
Clinical pipelines and trial milestones, congress intelligence, regulatory and HTA decisions, payer and pricing moves, competitor evidence and publication strategies — translated into implications for your evidence, access and launch plans.
Can you assess a licensing asset's market access potential?+
Yes. Our partnering due diligence evaluates the evidence package, comparator landscape and JCA / US payer-value readiness before the deal is signed.
Which congresses do you cover?+
ISPOR, ASCO, ESMO, ADA, AHA, EASL, ACR, BIO and other key scientific and partnering events, with rapid post-congress implication briefs.
Scope a Competitive Intelligence engagement
Share your objectives, timelines and target markets. We respond within one business day with next steps.